IQE continues to support TriQuint Semiconductor...
Cardiff, UK - 27 January 2011: IQE announces that its manufacturing facility in
Somerset, New Jersey will support TriQuint Semiconductor with a range of GaN
based wafer products following its recent award of a US Air Force Research
Laboratory (AFRL) contract.
TriQuint has been awarded the Defense Production Act Title III gallium nitride
(GaN) manufacturing development contract, the overall goal of which is to
increase yields, lower costs of high power, high frequency 100mm Gallium Nitride
wafers and improve time-to-market cycles for defense and commercial GaN
integrated circuits.
Gallium nitride is a key process technology that is leading advanced
semiconductor amplifier design for high-end radio-frequency (RF) communications
applications. The material system has inherent advantages over other
technologies including high voltage operation, greater power density (more power
per square millimeter) and efficiency. The on-going development of GaN-based
devices is leading to new smaller, more efficient amplifiers aimed at reducing
system size, weight and power consumption.
Mr Alex Ceruzzi, VP and General Manager of IQE's New Jersey facility commented:
"IQE is proud of its close working relationship with TriQuint Semiconductor in
supplying reliable, high-quality products ranging from high volume GaAs based RF
materials to emerging technologies such as 100mm GaN epitaxial wafers. We
appreciate TriQuint's continued commitment in selecting IQE to support this key
programme."
TriQuint is a leading global provider of innovative RF solutions and foundry
services for the world's leading communications, defense and aerospace companies
and has more than 25 years' experience in successfully transferring new
technologies into volume manufacturing processes. The Company supplies RF
innovation for consumer retail products including mobile devices, wireless LAN,
triple-play CATV systems, optical network and wireless infrastructure
applications
IQE manufactures a range of advanced semiconductor materials and has closely
supported TriQuint with a number of products including GaN for a number of
years.
The programme is expected to conclude in 2013 and is divided into three phases
with specific goals and assessment criteria at each milestone. The overall aim
of the new contract is to demonstrate integrated device technology that meets
stringent goals in terms of performance, cost and capacity, and whilst the
initial work will be designed for defense applications, it is anticipated that
the technologies will eventually migrate to future generations of consumer and
communications devices.
CONTACTS:
Technical/Sales: IQE RF (+1 732 271 5990)
Ivan Eliashevich
Press: IQE plc (+44 29 2083 9400)
Chris Meadows
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: IQE plc via Thomson Reuters ONE
[HUG#1481831]
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.